Apogee Therapeutics Shares Surge 19% on Positive Phase‑2 Atopic Dermatitis Data
Apogee Therapeutics' shares jumped 19% to $78.78 after the company released Phase‑2 APEX Part A results for its atopic dermatitis candidate, zumilokibart (APG777). The data showed 75‑85% of patients maintained EASI‑75 and 78‑86% achieved vIGA 0/1, prompting market enthusiasm and expectations for Phase‑3.
China Approves World’s First Implantable BCI
China's National Medical Products Administration has granted approval for the world's first commercially available implantable brain‑computer interface (BCI). Developed by Shanghai's Borui Kang Medical Technology, the system uses implanted electrodes to translate neural signals into commands for an assistive glove,...
Doctors Endorse Peptides as Effective and Favorable
Meanwhile: Anecdotal data: "I spoke lots of doctors, they all said peptides are great and they like them"
New Zealand Begins Genomics Testing Pilot and More Briefs
Te Whatu Ora Health New Zealand launched a two‑year genomics testing pilot with Illumina, targeting over 6,000 cancer and rare‑disease samples. The initiative seeks to localise roughly half of the 4,000 tests currently sent abroad, cutting the current $2.3 million annual overseas...
Valneva Shares Plunge 36% as Phase 3 Lyme Vaccine Trial Misses Primary Endpoint
Valneva SE saw its Nasdaq‑listed shares drop 36.39% to $6.57 after the Phase 3 VALOR trial of its Lyme disease vaccine, co‑developed with Pfizer, failed to meet the pre‑specified primary efficacy threshold. The result raises questions about the commercial viability...
Can a Mouse Be Cloned Indefinitely? Decades-Long Experiment Has Answers
Researchers at the University of Yamanashi completed a two‑decade experiment that serially cloned a single mouse for 58 generations before the process failed. Over 30,000 cloning attempts revealed that large‑scale DNA mutations, including loss of an entire chromosome, accumulated in...
Anesthetics as Emerging Therapeutics for Post-Traumatic Stress Disorder (PTSD): Bridging Bench and Bedside
A recent Molecular Psychiatry review highlights anesthetics as a promising new class of therapeutics for post‑traumatic stress disorder (PTSD). It outlines how NMDA‑receptor antagonists, α2‑adrenergic agonists, GABA‑A modulators and certain opioids can modulate fear circuitry and memory reconsolidation. Pre‑clinical models...
UCSF and Biohub Scientists Develop New Material to Grow More Consistent Lab Organs
Scientists at UCSF and the Biohub have engineered a seaweed‑derived alginate‑Matrigel composite that behaves like wet sand, enabling precise 3D bioprinting of stem cells. The material’s stress‑relaxation properties allow printed cells to stay positioned while the tissue self‑organizes, producing organoids...
HIV Remains Suppressed in Some Patients After Treatment Withdrawal
Scientists at Gladstone Institutes identified two host genes, DDIT4 and ZNF254, that act as molecular locks keeping HIV dormant after antiretroviral therapy (ART) cessation. Multi‑omic analysis of 75 participants from analytical treatment interruption trials linked higher expression of these genes,...
MRI-Guided Ablation as Effective as Surgery for Prostate Cancer Treatment
MRI‑guided TULSA ablation matches or exceeds robotic radical prostatectomy for intermediate‑risk prostate cancer. In the CAPTAIN trial of 211 patients, TULSA halved rates of erectile dysfunction and urinary incontinence, eliminated blood loss, and shortened hospital stays. Functional recovery was faster,...
Market Shifts Powering the Growth of Sterile Injectable Manufacturing
The sterile injectable contract manufacturing market is rapidly evolving as demand surges for both large‑scale biologics and niche, small‑batch therapies. Leading CDMOs are responding by expanding production capacity, building global redundancy, and investing heavily in specialized talent. Development and pre‑commercial...
Skin Regeneration Enabled by Embryonic Healing Mechanism in Mice
Harvard researchers published a Cell study showing that mouse skin can fully regenerate by reactivating an embryonic healing program that normally shuts down after birth. They identified excessive nerve growth—hyperinnervation—driven by fibroblast‑derived Cxcl12 as the key barrier to regeneration. Genetic...
Study Makes Promising Advances in Accurately Diagnosing Sepsis
Doctors at Liverpool and Cardiff University, together with 20 NHS hospitals, completed a large randomized trial of a rapid procalcitonin‑guided algorithm for suspected sepsis. The study of 7,667 emergency patients showed a 17% relative drop in mortality—from 16.6% to 13.6%—equating...
Brief 5‑MeO‑DMT Trip Yields Month‑Long Antidepressant Boost
One of the most remarkable things about 5-meo-DMT as an antidepressant is that the psychoactive experience is so brief. 10 minute peak, perhaps. 20 min total. And people seldom remember it well. Yet it has possibly the largest anti-depressant effect...
Cyborg Organoids Sense Glucose, Release Hormones for Diabetes
Bioengineers embedded soft, stretchable electronics into the tiny clusters to create “cyborg” organoids. These can mimic the pancreas, sensing glucose levels and releasing hormones. They could help build replacement cells for people with type 1 diabetes. https://spectrum.ieee.org/cyborg-stem-cell-therapy-for-diabetes
Bariatric Surgery in Adolescents 'Reprograms' Kidney Biology to Promote Recovery
A multi‑institutional study in the Journal of Clinical Investigation shows that vertical sleeve gastrectomy in adolescents with type 2 diabetes and obesity triggers profound molecular reprogramming of kidney cells, leading to functional recovery. Over a 12‑month follow‑up, participants lost weight, improved...
New Tongue-Swab TB Test Could Help Eradicate The Disease, WHO Says
The World Health Organization has endorsed a new near‑point‑of‑care molecular test that uses a simple tongue swab to detect tuberculosis in under an hour. Developed by PlusLife on its MiniDock platform, the device costs up to 90% less than GeneXpert...
Plastic Waste Transformed Into Parkinson’s Drug in Bioengineering First
Researchers at the University of Edinburgh have engineered bacteria to transform PET plastic waste into levodopa, a primary treatment for Parkinson’s disease. By inserting a seven‑gene, four‑step biosynthetic pathway into Escherichia coli, the team converted both industrial PET feedstock and...
Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
Since 1995 the FDA has moved from approving standard opioid products to implementing a comprehensive regulatory regime aimed at curbing misuse and overdose. Key milestones include the 2007 authority to require Risk Evaluation and Mitigation Strategies (REMS), a series of...
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
The FDA’s Center for Drug Evaluation and Research (CDER) launched the Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) to create a regulatory pathway for emerging manufacturing technologies. FRAME focuses on four priority technologies—end‑to‑end continuous manufacturing, distributed manufacturing (including non‑traditional sites),...
More Data Support Investigational Drug Combo for HIV Therapy
Phase 3 data presented at the 2026 Conference on Retroviruses and Opportunistic Infections show that the doravirine‑islatravir (DOR/ISL) two‑drug regimen met non‑inferiority criteria versus the standard bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) triple‑pill. At week 48, 91.8% of participants on DOR/ISL achieved viral suppression compared...
BTK Inhibition in CLL: Comparing Brukinsa and Jaypirca Approaches
BTK inhibitors have become the cornerstone of chronic lymphocytic leukemia therapy, replacing traditional chemotherapy. Brukinsa (zanubrutinib) is a second‑generation irreversible inhibitor that offers high selectivity and strong efficacy in treatment‑naïve or early‑relapse patients, with reduced cardiovascular risk. Jaypirca (pirtobrutinib) is...
FDA Drug Safety Communication: Safety Review Update of Recombinant Human Growth Hormone (Somatropin) and Possible Increased Risk of Death
The FDA updated its safety review of recombinant human growth hormone (somatropin) after the French SAGhE study raised concerns about a possible increased risk of death. The agency identified significant design flaws in the study and found no supporting evidence...
Reagent Spend Under 5%—Biotech Must Address Cost Gap
The thing to look at in biotech is your reagent costs as a % of your total research spending - inclusive of lab space, EHS, equipment maintenance, lab labor costs, etc. Lab data is the concrete output of biotech...
Keyboard Shortcuts Let You Reposition Plasmid Origins Instantly
I love this so much lololol You can use the arrow keys to circularly permute the plasmid to shift the reference origin as you please, you can use . and , to adjust the circularity of the...
When Doctors Prescribe Horoscopes: The Trouble With Biological Age Tests
Consumer epigenetic "biological age" tests promise a single number that reflects a person’s true health trajectory, but they actually measure DNA methylation patterns correlated with chronological age. Research‑grade clocks can predict mortality risk, yet the kits sold to patients lack...
Vibecoding Peaks Between PCRs, Meeting at 9
Vibecoding between PCR's has hit an all time high. See you at 9pm, Claude. https://t.co/8mJv5GJIut
ABVX Hires Entyvio Creator, Silencing CCO Doubts
$ABVX panicans were worried about a CCO hire and the company just went out & got the dude who launched Entyvio. Let's go! 🔥🔥🔥
Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite
Kevin Tang, chair of Aurinia’s board and head of Tang Capital Management, has seized the CEO role, replacing Peter Greenleaf, and installed fellow Tang Capital executives as COO, CFO, and CSO. Tang Capital expanded its ownership from 5.1% in September 2024 to 9.2%...
AI and Genomics Target Aging to Combat Chronic Disease
Aging underpins most chronic diseases and remains the biggest challenge to human health. Thank you @carninci for the opportunity to present @humantechnopole on aging, genomics and AI approaches to identify longevity targets and drugs. https://t.co/ysDGHfJeY0
Fermented Cordyceps Broth Improves Primary Insomnia in Trial
Effectiveness of fermentation broth of Cordyceps sinensis for primary insomnia: a randomized clinical trial with digital health tool https://t.co/g5iOuzkctO
Europa Biosite Introduces Rapid RNA Production Technologies
Europa Biosite has formed a strategic distribution partnership with Quantoom Biosciences to bring Quantoom’s Ntensify® mano and micro RNA production technologies to European researchers. The deal also anticipates future distribution of Quantoom’s Ncapsulate® LNP formulation kits. By adding rapid, high‑quality...
Consumer Longevity Research Gains Momentum with Ginkgo Cloud Lab
Really excited about the use of @Ginkgo Cloud Lab for consumers to do research in longevity and other consumer apps. These areas are less well-studied than you'd expect as US research funding is largely oriented towards disease. Fun chatting with @LongevityTech about...
FDA Approves Expanded Indication for Imcivree as Treatment for Hypothalamic Obesity
Rhythm Pharmaceuticals' Imcivree (setmelanotide) received FDA approval as the first treatment for acquired hypothalamic obesity, expanding its indication to adults and children aged four and older. The Phase III TRANSCEND trial demonstrated a 15.8% mean BMI reduction at 52 weeks, an...
US Patients Access Zegfrovy via Apex Oncology
Another win for Dizal, but how do US patients get hold of Zegfrovy? Via @ApexOnco -> https://t.co/4GVjyHS9vz https://t.co/bjjrnZkNL6
Stock Movers: Apogee, Synopsys, Norwegian Cruise (Podcast)
Apogee Therapeutics' shares jumped after the company released mid‑stage trial data showing its experimental drug deepened responses in patients with moderate‑to‑severe atopic dermatitis. Synopsys rose as activist investor Elliott Investment Management disclosed a multibillion‑dollar investment in the chip‑design software firm....
Rheumatology Enters the Gut-Brain-Immune Axis
Healio’s latest editorial highlights the expanding role of GLP‑1 receptor agonists in immune‑mediated inflammatory diseases, emphasizing weight‑independent anti‑inflammatory mechanisms. Emerging data suggest central nervous system GLP‑1 activation can modulate peripheral immunity, linking the gut‑brain‑immune axis. The FDA’s recent approval of...
QPX7728
Xeruborbactam (QPX‑7728) is a broad‑spectrum β‑lactamase inhibitor designed to revive the activity of β‑lactam antibiotics against multidrug‑resistant Gram‑negative bacteria. Developed by Qpex Biopharma and Shionogi, the molecule targets both serine‑ and metallo‑β‑lactamases, addressing a key resistance mechanism. Preclinical data show...
New Hope For Spina Bifida
A new prenatal therapy combining in‑utero surgery with placental stem‑cell patches, tested in the CuRe trial, has shown promising safety results for spina bifida. Six pregnancies underwent the procedure between 19 and 26 weeks, all delivering without infection, fluid leak,...
Integrated DNA Technologies Expands Into Clinical Diagnostics with First In Vitro Diagnostic
Integrated DNA Technologies (IDT) announced the launch of two in‑vitro diagnostic kits, Archer FUSION Plex‑HT Dx and VARIANT Plex‑HT Dx, marking its entry into the next‑generation sequencing (NGS) IVD market. Built on IDT’s proprietary anchored multiplex PCR chemistry, the kits offer targeted DNA and RNA...
The Six Biotech Companies in Portugal You Should Know About in 2026
Portugal’s biotech sector is gaining momentum, highlighted by BIO‑Europe Spring in Lisbon. Six home‑grown companies—Beat Therapeutics, BSIM Therapeutics, Exogenus, Immunethep, Mondego Bio and TechnoPhage—are advancing novel therapies ranging from DDR inhibitors for pancreatic cancer to exosome‑based wound treatments and bacteriophage...
Pfizer's Lyme Vaccine Data Remains Ambiguous, FDA Review Looms
As someone who lived in Vermont and still spends the summer there, it's disappointing to see the ambiguity in Pfizer's data on a new Lyme disease vaccine. It's a serious threat. Now we can move on to speculating on the...
Thymus Gland Emerges as Key to Healthy Aging
Don't take the time to read about the new landmark studies that put our thymus gland at center stage for healthy aging https://t.co/ENhIn2A2l3 https://t.co/oY2PLSenmf
CLL/SLL Treatment Choices Based on Various Factors
A population‑based study of 148 first‑line CLL/SLL patients in Alberta found that time‑limited venetoclax‑obinutuzumab was used in 51% of cases, while continuous BTK inhibitor therapy accounted for 44%. Patients with del(17p) or TP53 mutations chose BTK inhibitors in 84% of...
FDA OKs Fecal Transplants, Yet Access Declines
Paradox: The FDA approved some fecal transplants for C. difficile. But accessing treatment got harder. https://t.co/AFFyCGPeKW
Phase 3 Lyme Vaccine Shows Mixed Preliminary Results
The news is mixed in the preliminary results from a Phase 3 trial of a needed #Lyme disease vaccine, @matthewherper reports. https://t.co/bcbfeXchk1